Demir Baykal, MD
Cardiovascular Disease · Lawrenceville, GANPI 1336158104
Payments from drug & device makers
Across 317 payments — averaging $80.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$19K
- Actelion Pharmaceuticals US, Inc.$842
- Impulse Dynamics (USA) Inc.$764
- Merck$548
- Novartis$455
- Kestra Medical Technology Services, Inc.$452
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$16,96166%
- Travel & lodging$1,0884%
- Food & beverage$7,42729%
- Education$1881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 24 | $19,016 |
| Actelion Pharmaceuticals US, Inc. | 36 | $842 |
| Impulse Dynamics (USA) Inc. | 13 | $764 |
| Merck | 28 | $548 |
| Novartis | 27 | $455 |
| Kestra Medical Technology Services, Inc. | 36 | $452 |
| Johnson & Johnson | 47 | $426 |
| Cvrx, Inc. | 2 | $395 |
| Abbott | 5 | $354 |
| AstraZeneca | 9 | $338 |
| Pfizer | 12 | $263 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $217 |
| Inari Medical, Inc. | 1 | $193 |
| Heartflow, Inc. | 6 | $159 |
| Medtronic | 1 | $159 |
| Edwards Lifesciences | 1 | $151 |
| Boston Scientific | 6 | $137 |
| Amgen | 7 | $119 |
| Scpharmaceuticals Inc. | 5 | $115 |
| Boehringer Ingelheim | 5 | $93 |
| Kowa Pharmaceuticals America, Inc. | 5 | $78 |
| Bayer | 4 | $70 |
| Cordis US CORP. | 2 | $41 |
| Novo Nordisk | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Bridgebio Pharma, Inc. | 1 | $28 |
| Abiomed | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENITRAM$12,416
- REMODULIN$12,204
- TYVASO$12,204
- NONE$3,528
- OPTIMIZER$940
- Barostim Neo System$395
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$264
- LOKELMA$230
- FLOWTRIEVER CATHETER, S$193
- CT THROMBECTOMY SYSTEM KIT$193
- Micra$159
- SAPIEN 3 Ultra RESILIA$151
How this compares
$25,664 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 42 | $1,216,509 |
| AdempasRiociguat | 70 | $959,230 |
| Orenitram ErTreprostinil Diolamine | 28 | $753,008 |
| OpsumitMacitentan | 46 | $591,405 |
| EliquisApixaban | 384 | $451,325 |
| XareltoRivaroxaban | 161 | $211,477 |
| Ambrisentan | 48 | $173,430 |
| JardianceEmpagliflozin | 137 | $167,967 |
| EntrestoSacubitril/Valsartan | 99 | $119,026 |
| Tadalafil | 36 | $88,784 |
| FarxigaDapagliflozin Propanediol | 46 | $53,489 |
| AdcircaTadalafil | 14 | $49,254 |
| OzempicSemaglutide | 15 | $22,920 |
| BrilintaTicagrelor | 26 | $21,073 |
| Bosentan | 18 | $19,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan | $842 | $1,827,688106 claims |
| BayerAdempas | $70 | $959,23070 claims |
| PfizerEliquis | $263 | $451,325384 claims |
| Johnson & JohnsonXarelto | $426 | $211,477161 claims |
| Boehringer IngelheimJardiance | $93 | $167,967137 claims |
| NovartisEntresto | $455 | $119,02699 claims |
| AstraZenecaFarxiga, Brilinta | $338 | $74,56272 claims |
| United Therapeutics CorporationAdcirca | $19,016 | $49,25414 claims |
| Novo NordiskOzempic | $35 | $22,92015 claims |
| Esperion Therapeutics, Inc.Nexletol | $14 | $12,63112 claims |
| Sanofi-aventis U.S. LLCMultaq | $16 | $12,09211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Lawrenceville
- Alexis OkohLawrenceville$65K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.